S&P 500   4,562.60 (-0.10%)
DOW   36,132.43 (+0.02%)
QQQ   387.12 (-0.04%)
AAPL   192.87 (-0.28%)
MSFT   369.14 (-0.91%)
META   320.17 (+0.59%)
GOOGL   130.78 (-0.16%)
AMZN   146.04 (-0.57%)
TSLA   245.18 (+2.71%)
NVDA   463.11 (-0.55%)
NIO   8.02 (+7.94%)
BABA   72.16 (-0.30%)
AMD   119.43 (+0.89%)
T   16.98 (-1.39%)
F   10.80 (+1.89%)
MU   73.74 (+0.07%)
CGC   0.68 (+2.72%)
GE   120.64 (+0.34%)
DIS   92.01 (+1.34%)
AMC   6.98 (-0.57%)
PFE   29.18 (+0.31%)
PYPL   60.05 (+3.68%)
XOM   98.50 (-1.93%)
S&P 500   4,562.60 (-0.10%)
DOW   36,132.43 (+0.02%)
QQQ   387.12 (-0.04%)
AAPL   192.87 (-0.28%)
MSFT   369.14 (-0.91%)
META   320.17 (+0.59%)
GOOGL   130.78 (-0.16%)
AMZN   146.04 (-0.57%)
TSLA   245.18 (+2.71%)
NVDA   463.11 (-0.55%)
NIO   8.02 (+7.94%)
BABA   72.16 (-0.30%)
AMD   119.43 (+0.89%)
T   16.98 (-1.39%)
F   10.80 (+1.89%)
MU   73.74 (+0.07%)
CGC   0.68 (+2.72%)
GE   120.64 (+0.34%)
DIS   92.01 (+1.34%)
AMC   6.98 (-0.57%)
PFE   29.18 (+0.31%)
PYPL   60.05 (+3.68%)
XOM   98.50 (-1.93%)
S&P 500   4,562.60 (-0.10%)
DOW   36,132.43 (+0.02%)
QQQ   387.12 (-0.04%)
AAPL   192.87 (-0.28%)
MSFT   369.14 (-0.91%)
META   320.17 (+0.59%)
GOOGL   130.78 (-0.16%)
AMZN   146.04 (-0.57%)
TSLA   245.18 (+2.71%)
NVDA   463.11 (-0.55%)
NIO   8.02 (+7.94%)
BABA   72.16 (-0.30%)
AMD   119.43 (+0.89%)
T   16.98 (-1.39%)
F   10.80 (+1.89%)
MU   73.74 (+0.07%)
CGC   0.68 (+2.72%)
GE   120.64 (+0.34%)
DIS   92.01 (+1.34%)
AMC   6.98 (-0.57%)
PFE   29.18 (+0.31%)
PYPL   60.05 (+3.68%)
XOM   98.50 (-1.93%)
S&P 500   4,562.60 (-0.10%)
DOW   36,132.43 (+0.02%)
QQQ   387.12 (-0.04%)
AAPL   192.87 (-0.28%)
MSFT   369.14 (-0.91%)
META   320.17 (+0.59%)
GOOGL   130.78 (-0.16%)
AMZN   146.04 (-0.57%)
TSLA   245.18 (+2.71%)
NVDA   463.11 (-0.55%)
NIO   8.02 (+7.94%)
BABA   72.16 (-0.30%)
AMD   119.43 (+0.89%)
T   16.98 (-1.39%)
F   10.80 (+1.89%)
MU   73.74 (+0.07%)
CGC   0.68 (+2.72%)
GE   120.64 (+0.34%)
DIS   92.01 (+1.34%)
AMC   6.98 (-0.57%)
PFE   29.18 (+0.31%)
PYPL   60.05 (+3.68%)
XOM   98.50 (-1.93%)

BeiGene (BGNE) News Today

$183.24
-0.91 (-0.49%)
(As of 12:45 PM ET)
Compare
Today's Range
$180.32
▼
$184.35
50-Day Range
$158.67
▼
$201.58
52-Week Range
$156.56
▼
$280.62
Volume
94,324 shs
Average Volume
221,715 shs
Market Capitalization
$17.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$278.08
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media
SourceHeadline
marketbeat.com logoBellevue Group AG Has $1.82 Million Stock Holdings in BeiGene, Ltd. (NASDAQ:BGNE)
marketbeat.com - December 6 at 10:17 AM
benzinga.com logoBeiGene Stock (NASDAQ:BGNE) Earnings Dates and Earning Calls
benzinga.com - December 3 at 8:36 AM
benzinga.com logoBeiGene Stock (NASDAQ:BGNE) Dividends: History, Yield and Dates
benzinga.com - December 3 at 8:36 AM
MarketBeat logoBeiGene, Ltd. (NASDAQ:BGNE) Short Interest Up 23.3% in November
americanbankingnews.com - December 3 at 3:36 AM
finance.yahoo.com logoWall Street Analysts Think BeiGene, Ltd. (BGNE) Could Surge 44.28%: Read This Before Placing a Bet
finance.yahoo.com - November 30 at 2:16 PM
finance.yahoo.com logoBeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
finance.yahoo.com - November 29 at 6:43 PM
finance.yahoo.com logoBeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
finance.yahoo.com - November 28 at 9:59 AM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Karuna Therapeutics (KRTX) and Theseus Pharmaceuticals (THRX)
markets.businessinsider.com - November 23 at 7:45 PM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics
finance.yahoo.com - November 21 at 12:35 PM
finance.yahoo.com logoBeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
finance.yahoo.com - November 21 at 7:35 AM
msn.com logoBeiGene's Brukinsa gets Europe approval for follicular lymphoma
msn.com - November 17 at 10:35 AM
finance.yahoo.com logoBeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
finance.yahoo.com - November 17 at 10:35 AM
finance.yahoo.com logoBAKER BROS. ADVISORS LP Bolsters Position in BeiGene Ltd
finance.yahoo.com - November 15 at 7:19 AM
markets.businessinsider.com logoBuy Recommendation for BeiGene: Strong Sales, Potential FDA Approval, and Improved Operating Efficiencies
markets.businessinsider.com - November 14 at 10:49 PM
finance.yahoo.com logoWall Street Analysts Believe BeiGene, Ltd. (BGNE) Could Rally 32.87%: Here's is How to Trade
finance.yahoo.com - November 14 at 12:48 PM
finance.yahoo.com logoDecoding BeiGene Ltd (BGNE): A Strategic SWOT Insight
finance.yahoo.com - November 10 at 10:17 AM
de.investing.com logoBeiGene ADS: EPS übertrifft Schätzungen um 5,40 $ - Umsatz besser als erwartet
de.investing.com - November 9 at 11:44 PM
finanznachrichten.de logoBeiGene, Ltd.: BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
finanznachrichten.de - November 9 at 6:43 PM
finance.yahoo.com logoBeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
finance.yahoo.com - November 9 at 6:43 PM
finanznachrichten.de logoBeiGene, Ltd.: BeiGene to Present at the Jefferies London Healthcare Conference
finanznachrichten.de - November 8 at 10:06 AM
finance.yahoo.com logoBeiGene to Present at the Jefferies London Healthcare Conference
finance.yahoo.com - November 8 at 10:06 AM
finance.yahoo.com logoBeiGene, Ltd.'s (NASDAQ:BGNE) one-year returns climbed after last week's 8.9% gain, institutional investors must be happy
finance.yahoo.com - November 2 at 3:44 PM
businesswire.com logoBeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in ...
businesswire.com - October 27 at 12:28 PM
finance.yahoo.com logoBRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
finance.yahoo.com - October 20 at 10:42 AM
msn.com logoBeiGene: Staying On The Sidelines (Rating Downgrade)
msn.com - October 19 at 11:54 AM
msn.com logoBeiGene's Poster For Upcoming Conference Reveals Promising Lung Cancer Data
msn.com - October 18 at 3:44 PM
finance.yahoo.com logoBeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
finance.yahoo.com - October 17 at 5:32 PM
finance.yahoo.com logoBeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
finance.yahoo.com - October 17 at 5:32 PM
finance.yahoo.com logoBeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets
finance.yahoo.com - October 16 at 10:26 AM
marketbeat.com logoNational Bank of Canada FI Increases Holdings in BeiGene, Ltd. (NASDAQ:BGNE)
marketbeat.com - October 15 at 5:23 AM
finance.yahoo.com logoBeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
finance.yahoo.com - October 13 at 4:01 PM
marketbeat.com logoBaillie Gifford & Co. Sells 34,058 Shares of BeiGene, Ltd. (NASDAQ:BGNE)
marketbeat.com - October 12 at 3:16 PM
finance.yahoo.com logoBeiGene (NASDAQ:BGNE investor three-year losses grow to 43% as the stock sheds US$1.4b this past week
finance.yahoo.com - October 6 at 7:04 PM
marketbeat.com logoStockNews.com Upgrades BeiGene (NASDAQ:BGNE) to "Hold"
marketbeat.com - October 3 at 3:30 AM
marketbeat.com logoFirst Trust Direct Indexing L.P. Has $637,000 Holdings in BeiGene, Ltd. (NASDAQ:BGNE)
marketbeat.com - September 24 at 5:23 AM
marketbeat.com logoLeerink Partnrs Brokers Decrease Earnings Estimates for BeiGene, Ltd. (NASDAQ:BGNE)
marketbeat.com - September 22 at 7:13 AM
markets.businessinsider.com logoCitigroup Maintains Buy Rating for BeiGene: Here's What You Need To Know
markets.businessinsider.com - September 21 at 1:52 PM
marketbeat.com logoBeiGene (NASDAQ:BGNE) Price Target Raised to $290.00
marketbeat.com - September 21 at 7:38 AM
businesswire.com logoBeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA ® (tislelizumab)
businesswire.com - September 19 at 2:20 PM
businesswire.com logoBeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA
businesswire.com - September 19 at 2:20 PM
uk.finance.yahoo.com logoBeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
uk.finance.yahoo.com - September 19 at 9:20 AM
finanznachrichten.de logoBeiGene, Ltd.: BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA (tislelizumab)
finanznachrichten.de - September 19 at 9:20 AM
finance.yahoo.com logoBeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
finance.yahoo.com - September 19 at 9:20 AM
marketbeat.com logoBeiGene, Ltd. (NASDAQ:BGNE) Holdings Trimmed by SG Americas Securities LLC
marketbeat.com - September 18 at 6:30 AM
benzinga.com logoThe Latest Analyst Ratings for BeiGene
benzinga.com - September 12 at 6:37 PM
marketbeat.com logoProShare Advisors LLC Sells 1,002 Shares of BeiGene, Ltd. (NASDAQ:BGNE)
marketbeat.com - September 8 at 4:37 AM
thestreet.com logoCelgene Enters PD1 Market with BeiGene Deal
thestreet.com - September 1 at 11:23 PM
businesswire.com logoBeiGene to Present at the Morgan Stanley 21 st Annual Global Healthcare Conference
businesswire.com - September 1 at 3:59 AM
marketbeat.com logoRussell Investments Group Ltd. Boosts Stake in BeiGene, Ltd. (NASDAQ:BGNE)
marketbeat.com - August 22 at 4:46 AM
marketbeat.com logoConnor Clark & Lunn Investment Management Ltd. Reduces Position in BeiGene, Ltd. (NASDAQ:BGNE)
marketbeat.com - August 18 at 6:46 AM
Get BeiGene News Delivered to You Automatically

Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.



BGNE Media Mentions By Week

BGNE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BGNE
News Sentiment
▼
0.64

0.43
▲
Average
Medical
News Sentiment

BGNE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BGNE Articles
This Week
▼
5

4
▲
BGNE Articles
Average Week

Get BeiGene News Delivered to You Automatically

Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:BGNE) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -